GPX4 and prostate cancer: The same study demonstrated that GPX4 inhibition could then reduce the viability of a human-derived, erlotinib-insensitive prostate cancer organoid with high ZEB1 expression and that GPX4 deficiency halted the growth of a melanoma xenograft in mice.